Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of Aliskiren in essential hypertension
NCT00219037Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2004
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aliskiren in essential hypertension, sponsored by Novartis. Started Jun 2004; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00219037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00219037.